Actualización del Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNFα en las espondiloartritis, incluida la artritis psoriásica

Van der Linden, 2003, Classification of spondyloarthropathies, 1149 Dougados, 1991, Arthritis Rheum, 34, 1218, 10.1002/art.1780341003 Amor, 1990, Critères de classification des Spondylarthropathies, Rev Rhum Mal Ost, 57, 85 Braun, 1998, Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donnors, Arthritis Rheum, 41, 58, 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G Gran, 1993, The epidemiology of ankylosing spondylitis, Semin Arthritis Rheum, 22, 319, 10.1016/S0049-0172(05)80011-3 Braun, 2002, Mortality, course of disease and prognosis of patients with ankylosing spondylitis, Clin Exp Rheumatol, 20, S16 Koehler, 2000, Managing seronegative spondarthritides, Rheumatology, 39, 360, 10.1093/rheumatology/39.4.360 Clegg, 1999, Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study, Arthritis Rheum, 42, 2325, 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C Braun, 2006, Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial, Ann Rheum Dis, 65, 1147, 10.1136/ard.2006.052878 Mease, 2004, Recent advances in the management of psoriatic arthritis, Curr Opin Rheumatol, 16, 366, 10.1097/01.bor.0000129720.21563.b8 Calin, 2004, Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis, Ann Rheum Dis, 63, 1594, 10.1136/ard.2004.020875 Mease, 2000, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, Lancet, 356, 385, 10.1016/S0140-6736(00)02530-7 Van der Heijde, 2005, Efficacy and safety of infliximab in patients with spondylitis: results of a randomized, placebo-controlled trial (ASSERT), Arthritis Rheum, 52, 582, 10.1002/art.20852 Antoni, 2005, Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial, Ann Rheum Dis, 64, 1150, 10.1136/ard.2004.032268 Van der Heijde, 2006, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebocontrolled trial, Arthritis Rheum, 54, 2136, 10.1002/art.21913 Mease, 2005, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial, Arthritis Rheum, 52, 3279, 10.1002/art.21306 2005, Primer documento de consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF alfa en las espondiloartritis, Reumatol Clin, 1, 32, 10.1016/S1699-258X(05)72710-8 Van der Heijde, 2006, Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis, Ann Rheum Dis, 65, 1572, 10.1136/ard.2006.056747 Haibel, 2006, Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial, Arthritis Rheum, 54, 678, 10.1002/art.21563 Galor, 2006, Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation, Ophtalmology, 113, 2317, 10.1016/j.ophtha.2006.04.038 Delaunay, 2005, Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data, J Rheumatol, 32, 2183 Woolacott, 2006, Etanercept and infliximab for the treatment of psoriatic artritis: a systematic review, Clin Exp Rheumatol, 24, 587 Fernandez-Nebro, 2005, Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists, Am J Med, 118, 552, 10.1016/j.amjmed.2005.01.028 Gottenberg, 2003, Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy, Arthritis Rheum, 48, 2019, 10.1002/art.11163 Rosenbaum, 2002, Anti-TNFα therapy for eye involvement in spondyloarthropathy, Clin Exp Rheumatol, 20, S143 Garret, 1994, A new aproach to defining disease status in ankylosing spondylitis. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), J Rheumatol, 21, 2228 Heuft-Dorenbosch, 2004, The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index, Arthritis Rheum, 51, 154, 10.1002/art.20233 Stone, 2004, Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics, Arthritis Rheum, 51, 316, 10.1002/art.20414 Calin, 1994, A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index, J Rheumatol, 21, 2281 Tubach, 2006, Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis, Arthritis Care Res, 55, 960, 10.1002/art.22342 Dougados, 2001, Efficacy of celecoxib, a ciclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug, Arthritis Rheum, 44, 180, 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K Cantina, 2006, Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four week study, Arthritis Care Res, 55, 812, 10.1002/art.22236 Collantes-Estevez, 2005, Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies, Rheumatology (Oxford), 44, 1555, 10.1093/rheumatology/kei085 Kavanaug, 2005, The assessment of disease activity and outcomes in psoriatic arthritis patients, Clin Exp Rheumatol, 23, S142 Mease, 2006, Quality of life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatologic perspective, J Am Acad Dermatol, 54, 685, 10.1016/j.jaad.2005.10.008 Heuft-Dorenbosch, 2003, Assessment of enthesitis in ankylosing spondylitis, Ann Rheum Dis, 62, 127, 10.1136/ard.62.2.127 Fransen, 2005, The disease activity score and the EULAR response criteria, Clin Exp Rheumatol, 23, S93 Fransen, 2006, Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors, Ann Rheum Dis, 65, 1373, 10.1136/ard.2006.051706 Ritchlin, 2006, Therapies for psoriatic enthesopathy. A systematic review, J Rheumatol, 33, 1435 Helliwell, 2006, Therapies for dactylitis in psoriatic arthritis. A systematic review, J Rheumatol, 33, 1439 Soriano, 2006, Therapies for peripheral joint disease in psoriatic arthritis. A systematic review, J Rheumatol, 33, 1422 Kavanaugh, 2006, Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines, J Rheumatol, 33, 1417 Nash, 2006, Therapies for axial disease in psoriatic arthritis. A systematic review, J Rheumatol, 33, 1431 Van den Bosch, 2002, Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy, Arthritis Rheum, 46, 755, 10.1002/art.511 Pamuk, 2005, A patient with ankylosing spondylitis who presented with chronic necrotising aspergillosis. Report on one case and review of the literature, Clin Rheumatol, 24, 415, 10.1007/s10067-004-1047-8 Baeten, 2003, Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?, Ann Rheum Dis, 62, 829, 10.1136/ard.62.9.829 Ferraro-Peyret, 2004, Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study, Arthritis Res Ther, 6, 535, 10.1186/ar1440 De Keyser, 2004, Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis, Drugs, 64, 2793, 10.2165/00003495-200464240-00005 Rodríguez Valverde, 2006, III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide, Reumatol Clin, 2, S52, 10.1016/S1699-258X(06)73097-2 Oniankitan, 2004, Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C, J Rheumatol, 31, 107 Esteve, 2004, Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis, Gut, 53, 1363, 10.1136/gut.2004.040675 Calabrese, 2006, Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies, Ann Rheum Dis, 65, 983, 10.1136/ard.2005.043257 Wendling, 2005, Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy, Ann Rheum Dis, 64, 788, 10.1136/ard.2004.031187 Nathan, 2006, Hepatitis B and C virus infectios and anti-tumor necrosis factor therapy: Guidelines for clinical approach, J Gastroenterol Hepatol, 21, 1366, 10.1111/j.1440-1746.2006.04559.x Zein, 2005, Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study, J Hepatol, 42, 315, 10.1016/j.jhep.2004.11.025 Ellerin, 2003, Infections and anti-tumor necrosis factor therapy, Arthritis Rheum, 48, 3013, 10.1002/art.11301 Elkayam, 2004, The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis, Semin Arthritis Rheum, 33, 283, 10.1053/j.semarthrit.2003.10.003 Carmona, 2005, Registro español de acontecimientos adversos en enfermedades reumáticas (BIOBADASER). Informe de la situación a 14 de enero de 2005, Reumatol Clin, 1, 95, 10.1016/S1699-258X(05)72722-4 Listín, 2005, Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis Rheum, 52, 3403, 10.1002/art.21386 Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 Gómez-Reino, 2003, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors my predispose to significant increase in tuberculosis risk: a multicenter active surveillance report, Artritis Rheum, 48, 2122, 10.1002/art.11137 1992, Consenso nacional para el control de la tuberculosis en España, Med Clin (Barc), 98, 24 2002, Recomendaciones SEPAR. Normativa sobre la prevención de la tuberculosis, Arch Bronconeumol, 38, 441, 10.1016/S0300-2896(02)75259-9 American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-47 [actualización, Am J Respir Crit Care Med. 2001;164:1319-20]. Carmona, 2005, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis Rheum, 52, 1766, 10.1002/art.21043 Wallis, 2004, Granulomatous infectious diseases associated with tumor necrosis factor antagonists, Clin Infect Dis, 38, 1261, 10.1086/383317 Slifman, 2003, Listeria monocytogenes infection as a complication of treatment with anti tumor necrosis factor α-neutralizing agents, Arthritis Rheum, 48, 319, 10.1002/art.10758 Warris, 2001, Invasive pulmonary aspergillosis associated with infliximab therapy, N Engl J Med, 344, 1099, 10.1056/NEJM200104053441415 Lee, 2002, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept, Arthritis Rheum, 46, 2565, 10.1002/art.10583 Bergstrom, 2002, Coccidiomycosis (valley fever) occurring during infliximab therapy, Arthritis Rheum, 46, S169 Joven, 2005, Pregnancy in women receiving anti-TNF-alpha therapy. Experience in Spain, Arthritis Rheum, 49, S884 Salmon, 2006, Are we coming to terms with tumor necrosis factor inhibition in pregnancy?, Arthritis Rheum, 54, 2353, 10.1002/art.22027 Mohan, 2001, Demyelination occurring during anti-tumor necrosis factor a therapy for infflammatory arthritides, Arthritis Rheum, 44, 2862, 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W Setoguchi, 2006, Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis, Arthritis Rheum, 54, 2757, 10.1002/art.22056 Carmona, 2005, Registro español de acontecimientos adversos en enfermedades reumáticas (BIOBADASER). Informe de la situación a 14 de enero de 2005, Reumatol Clin, 1, 95, 10.1016/S1699-258X(05)72722-4 Wolfe, 2004, Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients, Arthritis Rheum, 50, 1740, 10.1002/art.20311 Geborek, 2005, Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas, Ann Rheum Dis, 64, 699, 10.1136/ard.2004.030528 Bongartz, 2006, Anti-TNF antibody therapy in Rheumatoid Arthritis and the risk of serious infections and malignancies. Systematic review and Meta-analysis of rare harmful effects in randomized controlled trials, JAMA, 295, 2275, 10.1001/jama.295.19.2275 Askling, 2006, Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study, Ann Rheum Dis, 65, 1184, 10.1136/ard.2005.047514 Hyrich, 2004, Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety, Ann Rheum Dis, 63, 1538, 10.1136/ard.2004.024737 Perez-Garcia, 2006, Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab, Rheumatology (Oxford), 455, 114, 10.1093/rheumatology/kei220 Flendrie, 2005, Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study, Arthritis Res Ther, 7, 666, 10.1186/ar1724 Cohen, 2007, Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: A case series, J Rheumatol, 34, 380 Paul, 2003, Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study, J Invest Dermatol, 120, 211, 10.1046/j.1523-1747.2003.12040.x